You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameReboxetine
Accession NumberDB00234  (APRD00198)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DavedaxNot Available
EdronaxNot Available
NoreboxNot Available
ProliftNot Available
SolvexNot Available
VestraNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Reboxetine mesilate
98769-84-7
Thumb
  • InChI Key: CGTZMJIMMUNLQD-STYNFMPRSA-N
  • Monoisotopic Mass: 409.155908767
  • Average Mass: 409.5
DBSALT000890
Categories
UNII947S0YZ36I
CAS number71620-89-8
WeightAverage: 313.397
Monoisotopic: 313.167793605
Chemical FormulaC19H23NO3
InChI KeyCBQGYUDMJHNJBX-RTBURBONSA-N
InChI
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
IUPAC Name
(2R)-2-[(R)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine
SMILES
[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1
Pharmacology
IndicationFor the treatment of clinical depression.
Structured Indications Not Available
PharmacodynamicsReboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders.
Mechanism of actionReboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Related Articles
AbsorptionReboxetine is rapidly and extensively absorbed following oral administration.
Volume of distributionNot Available
Protein binding98%
Metabolism

Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4.

Route of eliminationNot Available
Half life12.5 hours
ClearanceNot Available
ToxicityReports of seizures (rare) have been reported
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Reboxetine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Reboxetine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Reboxetine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Reboxetine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Reboxetine.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Reboxetine.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Reboxetine.Approved, Investigational
AmiodaroneThe metabolism of Reboxetine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Reboxetine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Reboxetine.Approved
AprepitantThe serum concentration of Reboxetine can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Reboxetine.Approved, Investigational
AtazanavirThe metabolism of Reboxetine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Reboxetine.Approved
AtomoxetineThe metabolism of Reboxetine can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Reboxetine.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Reboxetine.Approved, Vet Approved
BexaroteneThe serum concentration of Reboxetine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Reboxetine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Reboxetine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Reboxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Reboxetine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reboxetine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Reboxetine.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Reboxetine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Reboxetine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Reboxetine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Reboxetine.Approved
CarbamazepineThe metabolism of Reboxetine can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Reboxetine.Approved
CeritinibThe serum concentration of Reboxetine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Reboxetine.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Reboxetine.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Reboxetine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Reboxetine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Reboxetine.Approved
ClarithromycinThe metabolism of Reboxetine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Reboxetine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Reboxetine.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Reboxetine.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Reboxetine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Reboxetine.Approved, Nutraceutical
ClotrimazoleThe metabolism of Reboxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Reboxetine.Approved
CobicistatThe metabolism of Reboxetine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Reboxetine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Reboxetine.Approved
ConivaptanThe serum concentration of Reboxetine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Reboxetine.Approved
CrizotinibThe metabolism of Reboxetine can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Reboxetine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine.Approved
DabrafenibThe serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Reboxetine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Reboxetine.Approved
DarunavirThe metabolism of Reboxetine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Reboxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Reboxetine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Reboxetine.Approved
DeferasiroxThe serum concentration of Reboxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Reboxetine can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Reboxetine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Reboxetine.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Reboxetine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Reboxetine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Reboxetine.Approved
DihydroergotamineThe metabolism of Reboxetine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Reboxetine.Illicit
DiltiazemThe metabolism of Reboxetine can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Reboxetine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Reboxetine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Reboxetine.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Reboxetine.Approved, Investigational
DoxycyclineThe metabolism of Reboxetine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Reboxetine can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Reboxetine.Approved
EfavirenzThe serum concentration of Reboxetine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Reboxetine.Approved, Investigational
EnzalutamideThe serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Reboxetine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Reboxetine.Approved, Investigational
ErythromycinThe metabolism of Reboxetine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Reboxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Reboxetine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Reboxetine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Reboxetine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Reboxetine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Reboxetine.Approved
EtravirineThe serum concentration of Reboxetine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Reboxetine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Reboxetine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Reboxetine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Reboxetine.Approved
FluconazoleThe metabolism of Reboxetine can be decreased when combined with Fluconazole.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Reboxetine.Approved
FluvoxamineThe metabolism of Reboxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Reboxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Reboxetine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Reboxetine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Reboxetine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Reboxetine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Reboxetine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Reboxetine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Reboxetine.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Reboxetine.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Reboxetine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Reboxetine.Approved
IdelalisibThe serum concentration of Reboxetine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Reboxetine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Reboxetine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Reboxetine.Approved
IndinavirThe metabolism of Reboxetine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Reboxetine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Reboxetine.Approved, Investigational
IsavuconazoniumThe metabolism of Reboxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Reboxetine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Reboxetine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Reboxetine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Reboxetine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Reboxetine.Approved
KetoconazoleThe metabolism of Reboxetine can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Reboxetine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Reboxetine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Reboxetine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Reboxetine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Reboxetine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Reboxetine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Reboxetine.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Reboxetine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Reboxetine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Reboxetine.Approved
LopinavirThe metabolism of Reboxetine can be decreased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Reboxetine.Approved
LovastatinThe metabolism of Reboxetine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Reboxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Reboxetine can be increased when combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Reboxetine.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Reboxetine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Reboxetine.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Reboxetine.Approved, Illicit
MifepristoneThe serum concentration of Reboxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Reboxetine.Approved
MitotaneThe serum concentration of Reboxetine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Reboxetine.Approved, Investigational
ModafinilThe serum concentration of Reboxetine can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Reboxetine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Reboxetine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Reboxetine.Approved
NafcillinThe serum concentration of Reboxetine can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Reboxetine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Reboxetine.Approved, Vet Approved
NefazodoneThe metabolism of Reboxetine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Reboxetine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Reboxetine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Reboxetine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Reboxetine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Reboxetine.Approved
NilotinibThe metabolism of Reboxetine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Reboxetine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Reboxetine.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Reboxetine.Approved, Investigational
OlaparibThe metabolism of Reboxetine can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Reboxetine.Approved
OsimertinibThe serum concentration of Reboxetine can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Reboxetine.Approved, Vet Approved
PalbociclibThe serum concentration of Reboxetine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Reboxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Reboxetine.Approved
PentobarbitalThe metabolism of Reboxetine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Reboxetine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Reboxetine can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Reboxetine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Reboxetine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Reboxetine.Approved
PosaconazoleThe metabolism of Reboxetine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Reboxetine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Reboxetine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Reboxetine.Approved, Vet Approved
PrimidoneThe metabolism of Reboxetine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Reboxetine.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Reboxetine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Reboxetine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Reboxetine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Reboxetine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Reboxetine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Reboxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Reboxetine.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Reboxetine.Approved
RifabutinThe metabolism of Reboxetine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Reboxetine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Reboxetine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Reboxetine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Reboxetine.Approved, Investigational
RitonavirThe metabolism of Reboxetine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Reboxetine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Reboxetine.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Reboxetine.Approved, Vet Approved
SaquinavirThe metabolism of Reboxetine can be decreased when combined with Saquinavir.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Reboxetine.Approved
SildenafilThe metabolism of Reboxetine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Reboxetine.Approved
SiltuximabThe serum concentration of Reboxetine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Reboxetine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Reboxetine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Reboxetine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Reboxetine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Reboxetine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Reboxetine.Experimental
St. John's WortThe serum concentration of Reboxetine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Reboxetine can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Reboxetine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Reboxetine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Reboxetine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Reboxetine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Reboxetine.Approved
TelaprevirThe metabolism of Reboxetine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Reboxetine can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Reboxetine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Reboxetine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Reboxetine.Approved
TiclopidineThe metabolism of Reboxetine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Reboxetine.Approved
TocilizumabThe serum concentration of Reboxetine can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Reboxetine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Reboxetine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Reboxetine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Reboxetine.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Reboxetine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Reboxetine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Reboxetine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Reboxetine.Approved
VenlafaxineThe metabolism of Reboxetine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Reboxetine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Reboxetine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Reboxetine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Reboxetine.Approved
VoriconazoleThe metabolism of Reboxetine can be decreased when combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Reboxetine.Approved
ZiprasidoneThe metabolism of Reboxetine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. [PubMed:11192474 ]
  2. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60. [PubMed:7579027 ]
  3. Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40. [PubMed:10534319 ]
  4. Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. [PubMed:11249515 ]
External Links
ATC CodesN06AX18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9381
Caco-2 permeable+0.575
P-glycoprotein substrateSubstrate0.7914
P-glycoprotein inhibitor IInhibitor0.8825
P-glycoprotein inhibitor IINon-inhibitor0.5968
Renal organic cation transporterNon-inhibitor0.5581
CYP450 2C9 substrateNon-substrate0.8237
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5402
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8063
CYP450 2D6 inhibitorNon-inhibitor0.5687
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.6318
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5218
Ames testNon AMES toxic0.9141
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9372
Rat acute toxicity2.0972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7754
hERG inhibition (predictor II)Inhibitor0.717
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-171 °C (Mesylate salt)Not Available
water solubility8 mg/mL (Mesylate salt)Not Available
logP3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0223 mg/mLALOGPS
logP3.06ALOGPS
logP3.28ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity89.48 m3·mol-1ChemAxon
Polarizability34.51 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassPhenol ethers
Sub ClassNot Available
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenoxy compound
  • Phenol ether
  • Alkyl aryl ether
  • Aralkylamine
  • Monocyclic benzene moiety
  • Morpholine
  • Oxazinane
  • Dialkyl ether
  • Secondary aliphatic amine
  • Ether
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT: Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther. 2002 Nov;303(2):664-72. [PubMed:12388649 ]
  2. Wilson AA, Johnson DP, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S: Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 2003 Feb;30(2):85-92. [PubMed:12623106 ]
  3. Lin KS, Ding YS, Kim SW, Kil KE: Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography. Nucl Med Biol. 2005 May;32(4):415-22. [PubMed:15878511 ]
  4. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006 Apr;26(2):152-6. [PubMed:16633143 ]
  5. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531 ]
  6. Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. [PubMed:11249515 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23